Compare GSK plc (GSK) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Icl Group Ltd — how do they compare? GSK plc trades at $52.63 (market cap $101.34B), while Icl Group Ltd trades at $5.06 (market cap $6.57B). The key difference: GSK plc is far larger — about 15.4× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.74%). Which is the better fit depends on your goals.
| GSK | ICL | |
|---|---|---|
Market Cap | $101.34B | $6.57B |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $7.03 |
52-Week Low | $36.20 | $4.80 |
Enterprise Value | $121.95B | $9.14B |
Dividend Yield | 3.49% | 3.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
ICL trades at $5.01, up 1.62% with bearish technical signals despite recent earnings beats. The company maintains stable cash flow with $1.06B from operations in 2025, though revenue has declined from $10B in 2022 to $7.15B in 2025. Recent $800M senior notes offering strengthens liquidity while analyst sentiment remains cautious with 100% hold ratings.
ICL faces margin compression with net income margin dropping to 3.52% amid rising costs. The stock's 24.29 P/E suggests full valuation relative to earnings growth. Key risks include raw material inflation and foreign exchange volatility, though improved debt management provides financial stability for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
